Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy

OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of second-line nilotinib versus dasatinib for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML-CP) patients who are intolerant or resistant to imatinib and can transition to treatment-free remissio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonifacio, Massimiliano, Maheshwari, Vikalp, Tran, Diana, Agostoni, Gianluca, Filioussi, Kalitsa, Viana, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807738/
https://www.ncbi.nlm.nih.gov/pubmed/34297312
http://dx.doi.org/10.1007/s41669-021-00286-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807738/
https://www.ncbi.nlm.nih.gov/pubmed/34297312
http://dx.doi.org/10.1007/s41669-021-00286-3

Ejemplares similares